Personal information

Verified email domains

Health Policy, Drug Pricing, Pharmaceutical Policy
United Kingdom

Activities

Employment (4)

London School of Economics: London, GB

Employment
Source: check_circle
London School of Economics & Political Science

Brown University: Providence, US

2025-01-01 to present | Associate Professor (Health Services, Policy, and Practice)
Employment
Source: Self-asserted source
Olivier Wouters

London School of Economics and Political Science: London, GB

2019-09-02 to 2024-12-31 | Assistant Professor of Health Policy (Health Policy)
Employment
Source: Self-asserted source
Olivier Wouters

London School of Economics and Political Science: London, GB

2018-09-03 to 2019-09-01 | Fellow in Health Economics (Health Policy)
Employment
Source: Self-asserted source
Olivier Wouters

Education and qualifications (4)

Brown University: Providence, RI, US

Education
Source: check_circle
Brown University

London School of Economics and Political Science: London, GB

2013-09 to 2018-03 | Ph.D. (Health Economics)
Education
Source: Self-asserted source
Olivier Wouters

London School of Economics and Political Science: London, GB

2011-10-01 to 2012-12-16 | M.Sc. (Health Economics)
Education
Source: Self-asserted source
Olivier Wouters

Georgetown University: Washington, DC, US

2007-08-14 to 2011-05-21 | B.Sc. (School of Foreign Service)
Education
Source: Self-asserted source
Olivier Wouters

Works (50 of 57)

Items per page:
Page 1 of 2

Drug prices negotiated by medicare vs US net prices and prices in other countries

JAMA
2024-12-02 | Journal article | Author
SOURCE-WORK-ID:

be67fad8-ea94-447d-bc84-8c34e7a7d6a4

EID:

2-s2.0-85216946372

Contributors: Olivier Wouters; Sean D. Sullivan; Emma M. Cousin; Nico Gabriel; Irene Papanicolas; Inmaculada Hernandez
Source: check_circle
London School of Economics & Political Science

Differential legal protections for biologics vs. small-molecule drugs in the US

JAMA
2024-11-25 | Journal article | Author
SOURCE-WORK-ID:

b1763433-e697-4eec-87f3-ce912eb1f0a8

EID:

2-s2.0-85214054312

Contributors: Olivier Wouters; Matthew Vogel; William B. Feldman ; Reed F. Beall; Aaron S. Kesselheim; S. Sean Tu
Source: check_circle
London School of Economics & Political Science

Integrating price benchmarks and comparative clinical effectiveness to inform the medicare drug price negotiation program

Value in Health
2024-10-31 | Journal article | Author
SOURCE-WORK-ID:

5413723b-25fb-4b14-83ab-c3972e4f6ca8

EID:

2-s2.0-85202077305

Contributors: Sean D. Sullivan; Olivier Wouters; Emma M. Cousin; Ayuri S. Kirihennedige; Inmaculada Hernandez
Source: check_circle
London School of Economics & Political Science

Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014

Value in Health
2024-10-31 | Journal article | Author
SOURCE-WORK-ID:

1ad97491-386e-46d5-9631-0c15de16113f

EID:

2-s2.0-85200520865

Contributors: Olivier Wouters; Aaron S. Kesselheim; Jouni Kuha; Jeroen Luyten
Source: check_circle
London School of Economics & Political Science

Low- and middle-income countries experienced delays accessing new essential medicines, 1982–2024

Health Affairs
2024-10-07 | Journal article | Author
SOURCE-WORK-ID:

573e9ceb-3f4d-4c6f-b7e0-1339ee58e3a2

EID:

2-s2.0-85205831155

Contributors: Olivier Wouters; Jouni Kuha
Source: check_circle
London School of Economics & Political Science

Price benchmarks of drugs selected for medicare price negotiation and their therapeutic alternatives

Journal of Managed Care & Specialty Pharmacy
2024-08-01 | Journal article | Author
SOURCE-WORK-ID:

c554698c-e9b5-4d09-966a-209169dae0bd

EID:

2-s2.0-85200523235

Contributors: Inmaculada Hernandez; Emma M. Cousin; Olivier Wouters; Nico Gabriel; Teresa Cameron; Sean D. Sullivan
Source: check_circle
London School of Economics & Political Science

Health Technology Assessment in the US—a word of caution—reply

JAMA Internal Medicine
2024-07-01 | Other | Author
SOURCE-WORK-ID:

7806f8fc-5db0-4e3a-947b-a93639bd5ad4

EID:

2-s2.0-85193703322

Contributors: Olivier Wouters; Huseyin Naci; Irene Papanicolas
Source: check_circle
London School of Economics & Political Science

Quantifying research and development expenditures in the drug industry

JAMA network open
2024-06-28 | Other | Author
SOURCE-WORK-ID:

f3c9ef21-3db2-4ca2-8969-93f1eba9aa7e

EID:

2-s2.0-85197145251

Contributors: Olivier Wouters; Aaron S. Kesselheim
Source: check_circle
London School of Economics & Political Science

Lobbying in US health care

JNCCN
2024-05-01 | Journal article | Author
SOURCE-WORK-ID:

1b20514f-54f4-4a69-9898-ea85bd57b839

EID:

2-s2.0-85193552166

Contributors: Olivier Wouters
Source: check_circle
London School of Economics & Political Science

Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies

Journal of American Medical Association: Internal Medicine
2024-03-01 | Journal article | Author
SOURCE-WORK-ID:

9fe281a3-2657-4d2a-9842-10524b83733f

EID:

2-s2.0-85183998188

Contributors: Olivier Wouters; Huseyin Naci; Irene Papanicolas
Source: check_circle
London School of Economics & Political Science

Medicare drug price negotiation

Journal of Managed Care & Specialty Pharmacy
2024-03-01 | Journal article | Author
SOURCE-WORK-ID:

f5bd0165-ac31-4bef-ab88-d93cb44bb13b

EID:

2-s2.0-85186747618

Contributors: Inmaculada Hernandez; Emma Cousin; Olivier Wouters; Nico Gabriel; Teresa Cameron; Sean D. Sullivan
Source: check_circle
London School of Economics & Political Science

Investments in research and development for supplemental drug indications

JAMA Health Forum
2023-09-01 | Other | Author
SOURCE-WORK-ID:

3c652725-471d-4a76-a2aa-26e68574f9c5

EID:

2-s2.0-85172289849

Contributors: Kerstin N. Vokinger; Gellért Perényi; Olivier Wouters
Source: check_circle
London School of Economics & Political Science

The launch of the EU Health Emergency Preparedness and Response Authority (HERA)

Health Policy
2023-07-01 | Journal article | Author
SOURCE-WORK-ID:

657dd819-4ea9-4fe8-9a87-bfc3ba17c9f5

EID:

2-s2.0-85160730464

WOSUID:

001053717500001

Contributors: Olivier Wouters; Rebecca Forman; Michael Anderson; Elias Mossialos; Martin McKee
Source: check_circle
London School of Economics & Political Science

Divergent COVID-19 vaccine policies

Vaccine
2023-04-24 | Journal article | Author
SOURCE-WORK-ID:

e2a8d5bc-1f2a-4908-90e8-f0fa9ea9d1bf

EID:

2-s2.0-85151437173

Contributors: Robin van Kessel; Rebecca Forman; Ricarda Milstein; Alicja Mastylak; Katarzyna Czabanowska; Thomas Czypionka; Isabelle Durand-Zaleski; Anja Hirche; Magdalena Krysinska-Pisarek; Bjelle Roberts et al.
Source: check_circle
London School of Economics & Political Science

Transferable exclusivity extensions to stimulate antibiotic research and development

The Lancet Microbe
2023-03-01 | Other | Author
SOURCE-WORK-ID:

2d578021-9a34-4ec8-806a-7c2f92d5319b

EID:

2-s2.0-85149062270

Contributors: Michael Anderson; Olivier Wouters; Elias Mossialos
Source: check_circle
London School of Economics & Political Science

High drug prices are not justified by industry’s spending on research and development

BMJ
2023-02-15 | Journal article | Author
SOURCE-WORK-ID:

7adf3b43-ab98-480d-9aef-b65818dab756

EID:

2-s2.0-85148114709

Contributors: Aris Angelis; Roman Polyakov; Olivier Wouters; Els Torreele; Martin McKee
Source: check_circle
London School of Economics & Political Science

Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021

JAMA
2023-01-03 | Journal article | Author
SOURCE-WORK-ID:

159b165c-eaf7-4287-a1e4-1c53fc34ade4

EID:

2-s2.0-85145429794

Contributors: William B. Feldman; S. Sean Tu; Rasha Alhiary; Aaron S. Kesselheim; Olivier Wouters
Source: check_circle
London School of Economics & Political Science

Product Hopping in the Drug Industry — Lessons from Albuterol

New England Journal of Medicine
2022-09-29 | Journal article
Contributors: Olivier J. Wouters; William B. Feldman; S. Sean Tu
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018

JAMA network open
2022-09-26 | Journal article | Author
SOURCE-WORK-ID:

71544b9e-0ca2-48cd-a69a-e67bbe56c621

EID:

2-s2.0-85138596150

Contributors: Olivier Wouters; Lucas A. Berenbrok; Meiqi He; Yihan Li; Inmaculada Hernandez
Source: check_circle
London School of Economics & Political Science

Errors in source data for study of drug development costs

JAMA
2022-09-20 | Other | Author
SOURCE-WORK-ID:

6c9e04ef-9e63-467b-9b49-71f6dd322e5d

EID:

2-s2.0-85138180570

Contributors: Olivier Wouters; Martin McKee; Jeroen Luyten
Source: check_circle
London School of Economics & Political Science

The Challenges of Regulating Artificial Intelligence in Healthcare Comment on "Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It? - A Viewpoint Paper"

International Journal of Health Policy and Management
2022-09-19 | Journal article
Contributors: Martin McKee; Olivier J. Wouters
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Measuring health science research and development in Africa

Health Research Policy and Systems
2021-12-11 | Journal article | Author
SOURCE-WORK-ID:

5682dd92-d6fb-4adb-b854-39711186df7b

EID:

2-s2.0-85111775138

Contributors: Clare Wenham; Olivier Wouters; Catherine M. Jones; Pamela A. Juma; Rhona M. Mijumbi-Deve; Joëlle L. Sobngwi-Tambekou; Justin Parkhurst
Source: check_circle
London School of Economics & Political Science

Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic

The Lancet Regional Health - Europe
2021-10 | Journal article
Contributors: Mark Jit; Aparna Ananthakrishnan; Martin McKee; Olivier J. Wouters; Philippe Beutels; Yot Teerawattananon
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Challenges in ensuring global access to COVID-19 vaccines

The Lancet
2021-03-13 | Journal article | Author
SOURCE-WORK-ID:

b9888211-a2a9-42b5-86dd-19e5839595d0

EID:

2-s2.0-85101682415

Contributors: Olivier Wouters; Kenneth Shadlen; Maximilian Salcher-Konrad; Andrew J Pollard; Heidi J Larson; Yot Teerawattananon; Mark Jit
Source: check_circle
London School of Economics & Political Science

Vaccine nationalism risks prolonging the global pandemic

2021-02-24 | Interactive resource | Author
SOURCE-WORK-ID:

e4859af6-95dd-4500-a272-d1678dc0e6d8

Contributors: Olivier Wouters
Source: check_circle
London School of Economics & Political Science

Association between provincial income levels and drug prices in China over the period 2010–2017

Social Science & Medicine
2020-10 | Journal article
Contributors: Wunan Shi; Olivier J. Wouters; Gordon Liu; Elias Mossialos; Xiuyun Yang
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Wat kost onderzoek en ontwikkeling van een medicijn? Een oproep tot meer transparantie

Nederlands Tijdschrift voor Geneeskunde
2020-08-18 | Journal article | Author
SOURCE-WORK-ID:

fb8d4075-d970-41d7-a3a1-9d1a4dd280f4

EID:

2-s2.0-85090582321

Contributors: Jeroen Luyten; Martin McKee; Olivier Wouters
Source: check_circle
London School of Economics & Political Science

Research and development costs of new drugs

JAMA
2020-08-04 | Other | Author
SOURCE-WORK-ID:

7b229275-7e1c-443f-96df-420edb86ab15

WOSUID:

000561261900032

EID:

2-s2.0-85089163971

Contributors: Olivier Wouters; Martin McKee; Jeroen Luyten
Source: check_circle
London School of Economics & Political Science

Risks to health and the NHS in the post-Brexit era

BMJ (Clinical research ed.)
2020-06-16 | Journal article | Author
SOURCE-WORK-ID:

d101a69f-5fa0-479e-a8a5-6b26bb666914

EID:

2-s2.0-85086686627

Contributors: May C.I. van Schalkwyk; Holly Jarman; Tamara Hervey; Olivier Wouters; Pepita Barlow; Martin McKee
Source: check_circle
London School of Economics & Political Science

Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018.

JAMA internal medicine
2020-03-03 | Journal article
Source: Self-asserted source
Olivier Wouters
grade
Preferred source (of 2)‎

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.

JAMA
2020-03-01 | Journal article
Source: Self-asserted source
Olivier Wouters

Brexit and the European Medicines Agency—what next for the Agency and UK drug regulators?

JAMA Health Forum
2020-02-18 | Journal article | Author
SOURCE-WORK-ID:

6288f2d8-e40e-4d71-abbb-130a1358f785

EID:

2-s2.0-85111037257

Contributors: Olivier Wouters; Tamara Hervey; Martin McKee
Source: check_circle
London School of Economics & Political Science

The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period

Social Science & Medicine
2019-01 | Journal article
Contributors: Olivier J. Wouters; Dale M. Sandberg; Anban Pillay; Panos G. Kanavos
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Essays on prices, volumes and policies in generic drug markets in high- and middle-income countries

2018-12-06 | Dissertation or Thesis | Author
SOURCE-WORK-ID:

019e6ded-39c7-42f9-b5bf-292b05ec1775

Contributors: Olivier Wouters
Source: check_circle
London School of Economics & Political Science

A comparison of generic drug prices in seven European countries: a methodological analysis

BMC Health Services Research
2017 | Journal article
EID:

2-s2.0-85016507436

Contributors: Wouters, O.J.; Kanavos, P.G.
Source: Self-asserted source
Olivier Wouters via Scopus - Elsevier
grade
Preferred source (of 2)‎

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

The Milbank quarterly
2017-09-01 | Journal article
Source: Self-asserted source
Olivier Wouters
grade
Preferred source (of 2)‎

Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

The Milbank quarterly
2017-06-01 | Journal article
Source: Self-asserted source
Olivier Wouters
grade
Preferred source (of 2)‎

Health Care after the Great Recession: Financing Options for Sustainable and High‐quality Health Systems

Global Policy
2017-03 | Journal article
Contributors: Panos Kanavos; Olivier J. Wouters
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

Private Financing of Health Care in Times of Economic Crisis: a Review of the Evidence

Global Policy
2017-03 | Journal article
Contributors: Olivier J. Wouters; Martin McKee
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

Medical savings accounts: Assessing their impact on efficiency, equity and financial protection in health care

Health Economics, Policy and Law
2016 | Journal article
EID:

2-s2.0-84958242738

Contributors: Wouters, O.J.; Cylus, J.; Yang, W.; Thomson, S.; McKee, M.
Source: Self-asserted source
Olivier Wouters via Scopus - Elsevier
grade
Preferred source (of 2)‎

Pharmaceutical regulation in 15 European countries: review

Health Systems in Transition
2016 | Journal article | Author
SOURCE-WORK-ID:

fc39b914-3338-4353-beed-f3caaea22c7c

EID:

2-s2.0-85016261402

Contributors: Dimitra Panteli; Francis Arickx; Irina Cleemput; Guillaume Dedet; Helene Eckhardt; Emer Fogarty; Sophie Gerkens; Cornelia Henschke; Jennifer Hislop; Claudio Jommi et al.
Source: check_circle
London School of Economics & Political Science

Incentivizing nutrition: how to apply incentive mechanisms to accelerate improved nutrition outcomes: a practitioner’s compendium

2016-11-21 | Report | Author
SOURCE-WORK-ID:

5e0443cb-0239-47ac-8a62-9316ba04be79

Contributors: Luc Laviolette; Sudararajan Gopalan; Leslie Elder; Olivier Wouters
Source: check_circle
London School of Economics & Political Science

Incentivizing nutrition: incentive mechanisms to accelerate improved nutrition outcomes

2016-11-21 | Report | Author
SOURCE-WORK-ID:

198d7240-d6cf-41b5-b18e-3a4b098c1f78

Contributors: Luc Laviolette; Sudararajan Gopalan; Leslie Elder; Olivier Wouters
Source: check_circle
London School of Economics & Political Science

Pharmaceutical regulation in 15 European countries review.

Health systems in transition
2016-10-01 | Journal article
Source: Self-asserted source
Olivier Wouters

An assessment of the methodological quality of published network meta-analyses: A systematic review

PLoS ONE
2015 | Journal article
EID:

2-s2.0-84928812833

Contributors: Chambers, J.D.; Naci, H.; Wouters, O.J.; Pyo, J.; Gunjal, S.; Kennedy, I.R.; Hoey, M.G.; Winn, A.; Neumann, P.J.
Source: Self-asserted source
Olivier Wouters via Scopus - Elsevier
grade
Preferred source (of 2)‎

Early chronic kidney disease: Diagnosis, management and models of care

Nature Reviews Nephrology
2015 | Journal article
EID:

2-s2.0-84938213660

Contributors: Wouters, O.J.; O'Donoghue, D.J.; Ritchie, J.; Kanavos, P.G.; Narva, A.S.
Source: Self-asserted source
Olivier Wouters via Scopus - Elsevier
grade
Preferred source (of 2)‎

Erratum: An assessment of the methodological quality of published network meta-analyses: A systematic review (PLoS ONE (2015) 10:4 (e0121715) Doi:10.1371/journal.pone.0121715)

PLoS ONE
2015 | Journal article
EID:

2-s2.0-84941308739

Contributors: Chambers, J.D.; Naci, H.; Wouters, O.J.; Pyo, J.; Gunjal, S.; Kennedy, I.R.; Hoey, M.G.; Winn, A.; Neumann, P.J.
Source: Self-asserted source
Olivier Wouters via Scopus - Elsevier

Rethinking the appraisal and approval of drugs for type 2 diabetes

BMJ (Online)
2015 | Journal article
EID:

2-s2.0-84947708886

Contributors: Naci, H.; Lehman, R.; Wouters, O.J.; Goldacre, B.; Yudkin, J.S.
Source: Self-asserted source
Olivier Wouters via Scopus - Elsevier
grade
Preferred source (of 2)‎

Transitioning to a national health system in cyprus: A stakeholder analysis of pharmaceutical policy reform | Transition vers un nouveau système de santé national à Chypre: Analyse par les parties prenantes de la réforme des politiques pharmaceutiques | La transición a un sistema nacional de salud en Chipre: Un análisis de los interesados en la reforma de la política farmacéutica

Bulletin of the World Health Organization
2015 | Journal article
EID:

2-s2.0-84940736722

Contributors: Wouters, O.J.; Kanavos, P.G.
Source: Self-asserted source
Olivier Wouters via Scopus - Elsevier
grade
Preferred source (of 2)‎

Understanding the role of governance in the pharmaceutical sector: from laboratory to patient

Strengthening Health System Governance: Better Policies, Stronger Performance
2015-11-01 | Book chapter | Author
SOURCE-WORK-ID:

4fb4d610-5598-46da-b4b9-951c05a28802

Part of ISBN: 9780335261345
Contributors: Jonathan Cylus; Olivier Wouters; Panos Kanavos
Source: check_circle
London School of Economics & Political Science
Items per page:
Page 1 of 2

Peer review (10 reviews for 6 publications/grants)

Review activity for Drug discovery today. (1)
Review activity for Health policy. (1)
Review activity for Nature communications (1)
Review activity for PLOS global public health. (1)
Review activity for PLoS medicine. (3)
Review activity for PloS one. (3)